drugset / Trial / NCT00413959
VELCADE,Rituximab,Cyclophosphamide and Decadron
NaSingle-groupOpen-labelTreatment
Summary
Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.
Timeline
- Start
- 2006-08
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 400 mg/m2 | Oral |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |